US 8664273
Treatment of hepatitis C virus with telaprevir (VX-950) in patients non-responsive to treatment with pegylated interferon-alpha 2A/2B and ribavirin
granted A61KA61K31/497A61K31/7056
Quick answer
US patent 8664273 (Treatment of hepatitis C virus with telaprevir (VX-950) in patients non-responsive to treatment with pegylated interferon-alpha 2A/2B and ribavirin) held by Vertex Pharmaceuticals Incorporated expires Mon Feb 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Vertex Pharmaceuticals Incorporated
- Grant date
- Tue Mar 04 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 7
- CPC classes
- A61K, A61K31/497, A61K31/7056, A61K38/07, A61K38/21